A patient may have an upset stomach or a rash at the injection area, but these were not prolonged or required additional treatment
The LactMed database, maintained by the National Library of Medicine, now states that tirzepatide is usually undetectable in breastmilk with subcutaneous doses of up to 5 mg and that absorption by the infant is unlikely because it is probably partially destroyed in the infant's gastrointestinal tract and poorly absorbed orally
In general, the people most likely to be evaluated for medicines in this class are those whose excess weight is affecting health through conditions such as prediabetes, type 2 diabetes, high blood pressure, fatty liver disease, sleep apnea, or reduced physical function
Pinch approximately 2 to 5 cm of skin to lift the subcutaneous tissue away from underlying muscle
Any provider that ships tirzepatide without a medical evaluation should be avoided entirely